Interim Data from Accent Pancreatic Cancer Trial Supports Continuation of Trial

Release Highlights:

• Amplia Therapeutics Ltd. (ASX: ATX) has released interim data from its ACCENT trial, which combines its proprietary drug, narmafotinib, with chemotherapy for treatment of advanced pancreatic cancer. Data shows six patients with confirmed partial responses (PRs), indicating a sustained 30% or greater reduction in tumor size, while 19 of the 24 evaluable patients in total have recorded tumor shrinkage.
• Narmafotinib has demonstrated a favorable tolerability profile in this study, with no required dose reductions, allowing patients to safely continue on their initial dosing schedule. Patients in the trial have had a median duration on treatment of 136 days, notably longer than the 117-day average seen in historical chemotherapy-only data.
• Initial findings suggest that narmafotinib may enable a more thorough and non-invasive tumor reduction treatment than chemotherapy alone. Recruitment has resumed for the final trial cohort of 24 patients, with three already enrolled as of October 24, 2024. Amplia expects to complete this final phase of enrollment by the end of Q1 FY2025.